Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams

Learn more about the current and emerging role of BTK inhibitors in the optimal care of patients with relapsed/refractory MCL, and gain expert insight on personalized approaches to prevent, mitigate and manage the adverse events associated with BTK inhibitors, featuring an on-demand webcast and downloadable slideset from a live workshop series.

Share

Program Content

Activities

Relapsed or Refractory MCL
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2023

Activities

Advances in MCL
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 10, 2023

Expires: August 09, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Beigene, Ltd. and Lilly.

BeiGene, Ltd.

Lilly